Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$1.07MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Maria Zannes
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 57
- Beta
- -1.05
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -18.53
Financials
Revenue
$1.07M+81851.0%Net Income
$-5.28MEBITDA
$-5.20MFree Cash Flow
$-3.95MEPS (diluted)
$-5.89Shares Outstanding (diluted)
895.9K+14972.3%Operating Expenses
$3.40MCash & Debt
$2.55MRevenue by Segment (annual)
$4.98MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $6.16M | $-14.91M | $-129.90 |
| 2024 | $9.36M | $-9.04M | $-337.50 |
| 2023 | $2.53M | $-7.94M | $-409.50 |
| 2022 | $4.8K | $-8.15M | $-814.50 |
| 2021 | $0.00 | $-6.33M | $-1062.90 |
| 2020 | $0.00 | $-7.27M | $-445.50 |
| 2019 | $0.00 | $-3.31M | $-202.50 |
Valuation
BIAFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
88-30.00%Social Signal Score
Mentions (5)
- Newszacks.com·9d ago·Negative
BIAF Stock Dips Post Q3 Earnings Despite Rising Test Demand, Sales Down bioAffinity's third-quarter 2026 results show weaker laboratory revenues and wider losses despite rising CyPath Lung test demand and growing physician adoption.
View source ↗ - Newsbusinesswire.com·16d ago·Positive
bioAffinity Technologies Reports Third Quarter 2026 Results and Continued Momentum in CyPath® Lung Commercialization SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies reports third quarter 2026 results, continued momentum in CyPath Lung commercialization.
View source ↗ - Newsbusinesswire.com·47d ago·Neutral
bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026 SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #CyPathLung--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that sales of its CyPath® Lung test for lung cancer increased more than 100% through the third quarter of 2026 compared to 2025, reflecting continued growt…
View source ↗ - Newsbusinesswire.com·61d ago·Positive
bioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #AvMEDICAL--bioAffinity Technologies will present two posters related to the CyPath Lung diagnostic test for lung cancer at the 2026 NAVREF Annual Conference.
View source ↗ - Newsbenzinga.com·66d ago·Positive
BioAffinity Technologies Stock Surges Following Hong Kong Patent Grant Shares of BioAffinity Technologies Inc. (NASDAQ:BIAF) are surging Thursday afternoon following the grant of a key Hong Kong patent for its CyPath Lung diagnostic. The rally is also boosting BioAffinity's Warrants (NASDAQ:BIAFW), up nearly 20% late Thursday.
View source ↗
Earnings
Mon, Apr 5(in 4 months)
Consensus estimate $-27.00 per share
Typical surprise +58.9% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Nov 6$-5.89 vs $-31.50beat
- Fri, Aug 7$-9.60 vs $-31.50beat
- Fri, May 8$-0.81 vs $-2.40beat
- Fri, Mar 13$-1.11 vs $-2.70beat
- Fri, Nov 14$-4.74 vs $-2.70miss
- Thu, Aug 14$-5.10 vs $-3.00miss
Estimates and results for BIAF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BIAF officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in BIAF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
